Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|PHGKB
Last Posted: Feb 09, 2023
spot light Spotlight

Liquid Biopsy for Oral Cancer Diagnosis: Recent Advances and Challenges
Y Naito et al, J Per Med, February 8, 2023

Over the past two decades, liquid biopsy has been considered an attractive diagnostic tool for malignant tumors. Although biomarkers for oral cancer have not yet been adopted in clinical practice, many molecular candidates have been investigated for liquid biopsies in oral cancer diagnosis, such as the proteome, metabolome, microRNAome, extracellular vesicles, cell-free DNAs, and circulating tumor cells. This review will present recent advances and challenges in liquid biopsy for oral cancer diagnosis.

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
SA Tomlins et al, Comm Med, February 7, 2023

Using treatment data and genomic and transcriptomic tumor tissue profiling from an observational trial, we developed Immunotherapy Response Score (IRS), a pan-tumor predictive model of PD-(L)1 benefit. IRS real-world progression free survival (rwPFS) and overall survival (OS) prediction was validated in an independent cohort of trial patients.

What It’s Like to Learn You’re Going to Live Longer Than You Expected
DJ Lamas, NY Times, February 6, 2023

Molly was born in 1988 with cystic fibrosis, a genetic disease that leads to an early death from lung failure. But Ms. Pam is now 34. And thanks to a new drug that has revolutionized the treatment of this disease, she will likely live to celebrate her ??40th and even 50th birthdays. Her life expectancy has shifted drastically within her lifetime. It is a remarkable and complicated experience. And as science races forward with gene therapy and targeted cancer treatments that promise to turn terminal disease into chronic illness, it is also a lesson in what might be ahead.

Integration of artificial intelligence in lung cancer: Rise of the machine.
Colton Ladbury et al. Cell reports. Medicine 2023 2 100933

In lung cancer, several data points over a patient’s diagnostic and treatment course are relevant to optimizing outcomes in the form of precision medicine, and artificial intelligence (AI) provides the opportunity to use available data from molecular information to radiomics, in combination with patient and tumor characteristics, to help clinicians provide individualized care. In doing so, AI can help create models to identify cancer early in diagnosis and deliver tailored therapy on the basis of available information,

news Latest News and Publications
CXCR3 predicts the prognosis of endometrial adenocarcinoma. External Web Site Icon
He Dong et al. BMC medical genomics 2023 2 (1) 20
A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China. External Web Site Icon
Shuling Zhou et al. BMC cancer 2023 23(1) 84
A Focused Clinical Review of Lynch Syndrome. External Web Site Icon
Demetra Georgiou et al. Cancer management and research 2023 1567-85
A qualitative study of patients with Cancer of Unknown Primary: Perceptions of communication, understanding of diagnosis and genomic testing, and information needs. External Web Site Icon
Kamil Wolyniec et al. Psycho-oncology 2023
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. External Web Site Icon
Josephine M N Lopes Cardozo et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 JCO2201978
Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer. External Web Site Icon
McKenzie J White et al. Breast cancer research and treatment 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. External Web Site Icon
A Bayle et al. Annals of oncology : official journal of the European Society for Medical Oncology 2023
Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. External Web Site Icon
Edgar A Villavicencio et al. Frontiers in public health 2023 101090101
Comprehensive analysis of PTPN family expression and prognosis in acute myeloid leukemia. External Web Site Icon
Yong Liu et al. Frontiers in genetics 2023 131087938
Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences. External Web Site Icon
Sukh Makhnoon et al. The breast journal 2023 20221447545


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.